| Literature DB >> 33984818 |
Archana Kumari1, Piyush Ranjan2, Sakshi Chopra3, Divjyot Kaur3, Tanveer Kaur4, Ashish Datt Upadhyay5, Joshua Abraham Isaac6, Rhytha Kasiraj6, Bindu Prakash7, Parmeshwar Kumar8, Sada Nand Dwivedi5, Naval K Vikram7.
Abstract
BACKGROUND AND AIMS: The success of the COVID-19 vaccination program is dependent on people's knowledge and attitude regarding the vaccination program. Higher vaccine acceptance can be ensured by strengthening the facilitators and limiting the barriers being observed among the general population.Entities:
Keywords: COVID-19; Concerns; Immunisation; KAP; Survey
Mesh:
Substances:
Year: 2021 PMID: 33984818 PMCID: PMC8087578 DOI: 10.1016/j.dsx.2021.04.015
Source DB: PubMed Journal: Diabetes Metab Syndr ISSN: 1871-4021
Knowledge regarding the COVID-19 vaccines and vaccination programme.
| S.No | Population groups | Number of responses by participants (Percentage) | Association with socio-demographic correlates | |||||
|---|---|---|---|---|---|---|---|---|
| Correct | Incorrect | Don't know | Age | Gender | Socioeconomic group | Residence | ||
| 1. | Vaccine is legally mandatory | 749 (57.88) | 385 (29.76) | 160 (12.36) | n.s. | n.s. | p < 0.001 | p < 0.001 |
| 2. | When will the protective immunity achieved | 268 (20.76) | 781 (60.50) | 242 (18.74) | n.s. | n.s. | p < 0.05 | n.s. |
| Vaccination is indicated in | ||||||||
| 3. | Infants <1 years of age | 966 (74.71) | 102 (7.89) | 225 (17.40) | p < 0.001 | n.s. | p < 0.001 | n.s. |
| 4. | Children and adolescents <18 years of age | 690 (53.32) | 452 (34.93) | 152 (11.75) | p < 0.001 | n.s. | p < 0.001 | p < 0.001 |
| 5. | Adults >18 years | 1031 (79.74) | 187 (14.46) | 75 (5.80) | n.s. | n.s. | p < 0.05 | p < 0.05 |
| 6. | Pregnant ladies and lactating mothers | 752 (58.11) | 273 (21.10) | 269 (20.79) | n.s. | n.s. | p < 0.05 | p < 0.05 |
| 7. | Patients with chronic diseases like diabetes, hypertension and heart diseases | 844 (65.22) | 301 (23.26) | 149 (11.51) | p < 0.001 | n.s. | p < 0.001 | n.s. |
| 8. | Persons having active COVID-19 infection | 601 (46.45) | 479 (37.02) | 214 (16.54) | p < 0.001 | n.s. | p < 0.001 | p < 0.01 |
| 9. | Persons recovered from COVID-19 infection | 994 (76.82) | 158 (12.21) | 142 (10.97) | p < 0.001 | n.s. | p < 0.001 | p < 0.05 |
| 10. | Person allergic to food items/drugs | 545 (42.12) | 439 (33.93) | 310 (23.96) | p < 0.05 | n.s. | p < 0.01 | p < 0.05 |
| 11. | Immunocompromised patients | 479 (37.02) | 455 (35.16) | 360 (27.82) | n.s. | n.s. | n.s. | n.s. |
Footnote: n.s.- Non significant.
For all other questions the number of responses is 1294.
The number of responses for S.No. 2 is 1291.
The number of responses for S.No. 3 and 5 is 1293.
Source of information affecting opinion of the general population regarding COVID-19 vaccine and vaccination programme.
| S. No | Sources of knowledge affecting opinion regarding COVID-19 vaccination program participation | Number of responses by participants (Percentage) | Association with socio-demographic correlates | |||||
|---|---|---|---|---|---|---|---|---|
| Insignificant | Somewhat significant | Significant | Age | Gender | Socioeconomic group | Residence | ||
| 1. | National News channel and Radio | 236 (18.24) | 530 (40.96) | 528 (40.80) | p < 0.001 | n.s. | n.s. | n.s. |
| 2. | Government Agencies | 199 (15.38) | 506 (39.10) | 589 (45.52) | p < 0.01 | p < 0.01 | p < 0.01 | n.s. |
| 3. | Social Media | 330 (25.52) | 558 (43.16) | 405 (31.32) | p < 0.05 | n.s. | n.s. | p < 0.01 |
| 4. | Discussion amongst friends and family | 210 (16.23) | 660 (51.00) | 424 (32.77) | n.s. | n.s. | p < 0.01 | n.s. |
| 5. | Healthcare Provider | 174 (13.45) | 465 (35.94) | 655 (50.61) | n.s. | n.s. | p < 0.05 | n.s. |
Footnote: n.s.- Non significant.
For all other questions the number of responses is 1294.
The number of responses for S.No. 3 is 1293.
General attitude of the general population towards COVID-19 vaccine and vaccination programme.
| S.No | General attitude domain | Number of responses by participants (Percentage) | Association with socio-demographic correlates | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Strongly Disagree | Disagree | Neither agree nor disagree | Agree | Strongly Agree | Age | Gender | Socioeconomic group | Residence | ||
| 1. | Willingness to take the COVID-19 vaccine | 34 (2.63) | 39 (3.02) | 139 (10.75) | 337 (26.06) | 744 (57.54) | p < 0.001 | n.s. | p < 0.001 | p < 0.01 |
| 2. | Prefer natural immunity over acquired immunity by getting COVID-19 vaccine | 263 (20.32) | 371 (28.67) | 248 (19.17) | 222 (17.16) | 190 (14.68) | p < 0.001 | p < 0.05 | p < 0.001 | p < 0.01 |
| 3. | Willingness to pay for the COVID-19 vaccine | 45 (3.48) | 98 (7.57) | 175 (13.52) | 467 (36.09) | 509 (39.34) | p < 0.001 | p < 0.01 | p < 0.001 | p < 0.01 |
| 4. | Willingness to recommend vaccine to friends and family | 29 (2.24) | 54 (4.17) | 140 (10.82) | 409 (31.61) | 662 (51.16) | p < 0.001 | n.s. | p < 0.001 | p < 0.05 |
Footnote: n.s.- Non significant.
For all other questions the number of responses is 1294.
The number of responses for S.No. 1 is 1293.
Facilitators driving the acceptance of COVID-19 vaccine amongst general population.
| S. No | Facilitators driving the acceptance of the vaccine | Number of responses by participants (Percentage) | Association with socio-demographic correlates | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Strongly Disagree | Disagree | Neither Disagree nor agree | Agree | Strongly agree | Age | Gender | Socioeconomic Group | Residence | ||
| 1. | No harm in taking the COVID-19 vaccine | 16 (1.24) | 72 (5.56) | 208 (16.07) | 465 (35.94) | 533 (41.19) | p < 0.001 | n.s. | p < 0.001 | n.s. |
| 2. | Protection against COVID-19 infection | 8 (0.62) | 52 (4.02) | 190 (14.68) | 539 (41.65) | 505 (39.03) | p < 0.001 | p < 0.05 | p < 0.001 | n.s. |
| 3. | Availability of COVID-19 vaccine free of cost | 36 (2.78) | 126 (9.74) | 287 (22.18) | 471 (36.40) | 374 (28.90) | n.s. | p < 0.001 | n.s. | p < 0.01 |
| 4. | Recommendation from healthcare professional/doctor | 27 (2.09) | 125 (9.66) | 247 (19.09) | 462 (35.70) | 433 (33.46) | p < 0.01 | p < 0.01 | n.s. | n.s. |
| 5. | More benefits of getting the COVID-19 vaccine over its risks | 16 (1.24) | 83 (6.42) | 244 (18.87) | 466 (36.04) | 484 (37.43) | p < 0.001 | p < 0.05 | p < 0.001 | n.s. |
| 6. | Taking COVID-19 vaccine is a societal responsibility | 22 (1.70) | 58 (4.47) | 174 (13.45) | 487 (37.64) | 553 (42.74) | p < 0.001 | n.s. | p < 0.001 | n.s. |
| 7. | Sufficient data regarding the vaccine's safety and efficacy is released by the government | 47 (3.63) | 140 (10.82) | 270 (20.86) | 483 (37.33) | 354 (27.36) | p < 0.05 | p < 0.05 | n.s. | p < 0.05 |
| 8. | Many people are taking the COVID-19 vaccine | 28 (2.16) | 114 (8.81) | 177 (13.68) | 555 (42.89) | 420 (32.46) | p < 0.05 | n.s. | p < 0.05 | p < 0.001 |
| 9. | Will help in eradicating the COVID-19 infection | 26 (2.01) | 66 (5.10) | 247 (19.09) | 528 (40.80) | 427 (33.00) | p < 0.05 | n.s. | p < 0.05 | n.s. |
| 10. | Role models/political leaders/senior doctors/scientists have taken the COVID-19 vaccine | 62 (4.80) | 87 (6.73) | 236 (18.25) | 467 (36.12) | 441 (34.11) | p < 0.01 | n.s. | n.s. | n.s. |
Footnote: n.s.- Non-significant.
For all other questions the number of responses is 1294.
The number of responses for S.No. 5 and 10 is 1293.
Barriers related to COVID-19 vaccine hesitancy amongst general population.
| S.No | Barriers related to vaccine hesitancy | Number of responses by participants (Percentage) | Association with socio-demographic correlates | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Strongly Disagree | Disagree | Neither agree nor disagree | Agree | Strongly | Age | Gender | Socioeconomic group | Residence | ||
| 1. | Lack of easy availability of COVID-19 vaccine | 109 (8.42) | 383 (29.60) | 342 (26.43) | 365 (28.21) | 95 (7.34) | p < 0.001 | n.s. | p < 0.001 | p < 0.001 |
| 2. | Immediate serious side effects after taking COVID-19 vaccine | 86 (6.65) | 341 (26.35) | 475 (36.71) | 305 (23.57) | 87 (6.72) | p < 0.05 | p < 0.05 | p < 0.05 | p < 0.05 |
| 3. | COVID-19 vaccine may be faulty or fake | 199 (15.38) | 433 (33.46) | 412 (31.84) | 181 (13.99) | 69 (5.33) | p < 0.001 | n.s. | p < 0.001 | p < 0.05 |
| 4. | COVID-19 vaccine was rapidly developed and approved. | 50 (3.86) | 187 (14.45) | 336 (25.97) | 558 (43.12) | 163 (12.60) | p < 0.05 | n.s. | n.s. | n.s. |
| 5. | COVID-19 vaccine might have unforeseen future effects. | 67 (5.18) | 266 (20.56) | 500 (38.64) | 366 (28.28) | 95 (7.34) | n.s. | n.s. | n.s. | n.s. |
| 6. | COVID-19 vaccine is being promoted for commercial gains of pharmaceutical companies. | 189 (14.61) | 378 (29.21) | 442 (34.16) | 178 (13.76) | 107 (8.26) | p < 0.01 | n.s. | p < 0.001 | p < 0.05 |
Footnote: n.s.- Non-significant.
For all questions the number of responses is 1294.